Cargando…

Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma

Transarterial radioembolization (TARE) is a well‐established therapy for intermediate and advanced tumor stages of hepatocellular carcinoma (HCC). Treatment‐associated toxicities are rare. Previous studies have outlined that the prognosis after TARE is determined primarily by tumor stage and liver f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reincke, Marlene, Schultheiss, Michael, Doppler, Michael, Verloh, Niklas, Uller, Wibke, Sturm, Lukas, Thimme, Robert, Goetz, Christian, Bettinger, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592795/ https://www.ncbi.nlm.nih.gov/pubmed/36064940 http://dx.doi.org/10.1002/hep4.2072

Ejemplares similares

Predictive Value of [(99m)Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [(90)Y]-TARE: A Single-Center Experience
por: Doppler, Michael, et al.
Publicado: (2023)

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
por: Roehlen, Natascha, et al.
Publicado: (2023)

Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis
por: Sturm, Lukas, et al.
Publicado: (2023)

Diagnostic Accuracy of Indocyanine Green Clearance Test for Different Stages of Liver Fibrosis and Cirrhosis
por: Luerken, Lukas, et al.
Publicado: (2023)

Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
por: Brunner, Thomas B., et al.
Publicado: (2021)

Biliary Leak after Pediatric Liver Transplantation Treated by Percutaneous Transhepatic Biliary Drainage—A Case Series
por: Doppler, Michael, et al.
Publicado: (2023)

Controlled flow reduction of an iliacoportal shunt graft for portal vein arterialization in a pediatric patient
por: Kulka, Charlotte, et al.
Publicado: (2023)

Transarterial radioembolization for hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2016)

Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Vardar, Baran U, et al.
Publicado: (2022)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience
por: Bettinger, Dominik, et al.
Publicado: (2017)

Combining Immunotherapy with Transarterial Radioembolization
por: Balaban Genc, Zeynep Ceren, et al.
Publicado: (2023)

Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy
por: Feng, Rui, et al.
Publicado: (2023)

Plasma Cyclic Guanosine Monophosphate Is a Promising Biomarker of Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis
por: Sturm, Lukas, et al.
Publicado: (2022)

Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium
por: Girardet, Raphaël, et al.
Publicado: (2020)

Proton pump inhibitor treatment aggravates bacterial translocation in patients with advanced cirrhosis and portal hypertension
por: Sturm, Lukas, et al.
Publicado: (2023)

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report
por: Ljuboja, Damir, et al.
Publicado: (2020)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma
por: Chan, Hui-Wen, et al.
Publicado: (2022)

Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?
por: Benkö, Tamás, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

Decreased Platelet Aggregation in Patients with Decompensated Liver Cirrhosis and TIPS Implantation
por: Nassar, Asala, et al.
Publicado: (2023)

Nonsurgical Therapeutic Options in Portal Vein Thrombosis
por: Schultheiß, Michael, et al.
Publicado: (2014)

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
por: Hur, Moon Haeng, et al.
Publicado: (2023)

Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients
por: Ballı, Hüseyin Tuğsan, et al.
Publicado: (2023)

Application of A U-Net for Map-like Segmentation and Classification of Discontinuous Fibrosis Distribution in Gd-EOB-DTPA-Enhanced Liver MRI
por: Strotzer, Quirin David, et al.
Publicado: (2022)

Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
por: Chung, Sung Won, et al.
Publicado: (2023)

Retrospective SPECT/CT dosimetry following transarterial radioembolization
por: Thompson, Briana C., et al.
Publicado: (2021)

Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yang, Yi, et al.
Publicado: (2018)

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
por: WENG, ZHIHONG, et al.
Publicado: (2013)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
por: Yim, Sun Young, et al.
Publicado: (2022)

Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study
por: Carrión, Laura, et al.
Publicado: (2023)

Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres
por: Bouvry, C., et al.
Publicado: (2018)

Transarterial radioembolization with Yttrium-90: current status and future prospects
por: Yang, Hua-Yu, et al.
Publicado: (2020)

Survival prediction using the Freiburg index of post-TIPS survival (FIPS) in critically ill patients with acute- on chronic liver failure: A retrospective observational study
por: Luxenburger, Hendrik, et al.
Publicado: (2022)

Novel (175)Yb-Poly (L-Lactic Acid) Microspheres for Transarterial Radioembolization of Unrespectable Hepatocellular Carcinoma
por: Jamre, Mina, et al.
Publicado: (2019)

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study
por: Lam, Marnix, et al.
Publicado: (2022)

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
por: Goh, Myung Ji, et al.
Publicado: (2020)

Diastolic dysfunction is associated with cardiac decompensation after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis
por: Schneider, Hannah, et al.
Publicado: (2023)

Validation of color Doppler ultrasound and computed tomography in the radiologic assessment of non-malignant acute splanchnic vein thrombosis
por: Sturm, Lukas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_35kbe4uu0q46dvjbst2hfa6od4